Potential of CXCR4/CXCL12 Chemokine Axis in Cancer Drug Delivery
Current Pharmacology Reports, ISSN: 2198-641X, Vol: 2, Issue: 1, Page: 1-10
2016
- 54Citations
- 48Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations54
- Citation Indexes54
- 54
- CrossRef32
- Captures48
- Readers48
- 48
Review Description
This review discusses the potential of CXCR4 chemokine receptor in the design of anticancer and antimetastatic drug delivery systems. The role of CXCR4 in cancer progression and metastasis is discussed in the context of the development of several types of drug delivery strategies. Overview of drug delivery systems targeted to cancers that overexpress CXCR4 is provided, together with the main types of CXCR4-binding ligands used in targeting applications. Drug delivery applications that take advantage of CXCR4 inhibition to achieve enhanced anticancer and antimetastatic activity of combination treatments are also discussed.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84993941069&origin=inward; http://dx.doi.org/10.1007/s40495-015-0044-8; http://www.ncbi.nlm.nih.gov/pubmed/27088072; http://link.springer.com/10.1007/s40495-015-0044-8; https://dx.doi.org/10.1007/s40495-015-0044-8; https://link.springer.com/article/10.1007/s40495-015-0044-8; http://link.springer.com/article/10.1007%2Fs40495-015-0044-8; https://link.springer.com/content/pdf/10.1007%2Fs40495-015-0044-8.pdf; http://link.springer.com/article/10.1007/s40495-015-0044-8/fulltext.html
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know